SARS
Study shows superior activity of Alferon N against SARS
Published in Hepatitis Weekly, May 17th, 2004
The study, "Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs," suggests Hemispherx' s lead drug, Alferon N Injection, tested among 19 clinically approved compounds from several major antiviral pharmacologic classes, exhibits the most potent antiviral activity in an in-vitro model of SARS-CoV infection and is a potential drug for in-vivo research. Companies contributing approved products included Roche, Schering-Plough, GlaxoSmithKline, Serono, Merck, Schering, AG, Novartis,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-05-17)
More Articles from Hepatitis Weekly
- Cancer Risk Factor
Unique gene sets distinguish cirrhosis patients with a risk for liver cancer - Chronic Liver Disease
Pioglitazone shows promise for treating non-alcoholic steatohepatitis - Immunology
Hepatitis C patients have fibrosis progression when T cell response falters - Transgenics
New transgenic mice could serve as models for hepatitis B-related liver cancer - Transplant Medicine
Erythropoietin may benefit patients with post-liver-transplant anemia - Addiction Medicine
Beliefs about HCV status affect drug users' health-related quality of life - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
